Mersana Therapeutics (MRSN) Now Covered by Analysts at HC Wainwright
HC Wainwright initiated coverage on shares of Mersana Therapeutics (NASDAQ:MRSN) in a research note released on Thursday, MarketBeat.com reports. The brokerage issued a buy rating on the stock.
A number of other research analysts have also recently weighed in on the stock. ValuEngine raised shares of Mersana Therapeutics from a strong sell rating to a sell rating in a research report on Friday, February 2nd. Zacks Investment Research raised shares of Mersana Therapeutics from a sell rating to a hold rating in a research report on Thursday, January 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $23.67.
Mersana Therapeutics (MRSN) opened at $15.36 on Thursday. Mersana Therapeutics has a 12-month low of $12.45 and a 12-month high of $21.01.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.